Aleve Warning Gives Pfizer Some Relief, But Is New Headache For FDA
Executive Summary
Data from a National Institutes of Health study on Alzheimer's disease prevention showing a cardiovascular safety signal for naproxen present a new challenge for FDA in regulating COX-2 inhibitors
You may also be interested in...
Graham Meta-Analysis Ultimately Positive For Celebrex, Bextra
FDA Office of Drug Safety Associate Director for Science & Medicine David Graham's controversial presentation of unpublished studies on the safety of COX-2 inhibitors ultimately benefited certain COX-2s and raised questions about others in the class during a joint FDA advisory committee review
Graham Meta-Analysis Ultimately Positive For Celebrex, Bextra
FDA Office of Drug Safety Associate Director for Science & Medicine David Graham's controversial presentation of unpublished studies on the safety of COX-2 inhibitors ultimately benefited certain COX-2s and raised questions about others in the class during a joint FDA advisory committee review
Vioxx Cardiovascular Risk Is Unique To Molecule, Pfizer And Novartis Tell FDA
The cardiovascular safety signal observed in Merck's Vioxx may be caused by the formation of potentially toxic rofecoxib metabolites, Pfizer states in its briefing documents for FDA's upcoming review of COX-2 inhibitors